Novozymes delivers strong half year results and narrows full-year outlook upwards

Novozymes delivered solid earnings and double-digit organic sales growth in both the first half and in the second quarter. Despite the volatile market environment, the company narrows its full-year organic sales outlook upwards from 4-8% to now 6-8% and raises EBIT-margin expectations from 25-26% to now 26-27%.

COPENHAGEN, Denmark – August 11, 2022. Novozymes delivers 10% organic sales growth and an EBIT-margin of 26% in the first half of the year, with 18% organic sales growth in DKK. Good momentum and strong half year and Q2 results have led to a narrowed full-year organic sales growth outlook to 6-8%.

“We deliver strong results for the first half of 2022 and growth is broad-based across the business. In fact, we deliver double-digit organic sales growth in four out of five business areas and in both developing and emerging markets. Our well-diversified portfolio and operational excellence prove the value our solutions generate to our customers. We are executing very well across our portfolio and markets, and in line with our strategic direction,” says Ester Baiget, President & CEO, and continues:

“Following a strong first half of the year we narrow our full-year outlook upwards to 6-8% organic sales growth, and we continue to expect solid margins and returns despite the significant pressure from input and logistic costs. This is a clear testament that our positioning and product portfolio is strong, and that we are able to drive our strategy forward balancing short-term execution with a clear long-term focus. We are ready to show the world the power of biotech.”

During the first half of the 2022 financial year, Novozymes has launched six new products. Four are launched in the second quarter covering efficient yeast solutions in Bioenergy, growth stimulators for broad acre crops in agriculture, and a solution for soap bars in Household Care for the emerging markets, allowing for longer storage times without losing efficacy.

Business area results 

For the first half of the 2022 financial year, organic performance by business area were 0% (4% in Q2) in Household Care, 10% (3% in Q2) in Food, Beverages & Human Health, 23% (19% in Q2) in Bioenergy, 13% (17% in Q2) in Grain & Tech Processing, and 14% (17% in Q2) in Agriculture, Animal Health & Nutrition.
Sales in Household Care in both the first half of the year and in Q2 was driven by solid performance in Emerging Markets. Sales in Q2 was negatively impacted by the war in Ukraine. Overall, the performance was in line with expectations.

Regional results

For the first half of the 2022 financial year, organic growth rates by geography were 7% (3% in Q2) in Europe, Middle East & Africa, 12% (14% in Q2) in North America, 9% (13% in Q2) in Asia Pacific, and 19% (23% in Q2) in Latin America.

Sales in emerging markets grew 10% (12% in Q2) organically and developed markets grew 10% (9% in Q2) organically.

Financial outlook for 2022

Novozymes has delivered solid first-half performance of 10% organic sales growth and narrows its full-year outlook range from 4-8% to now 6-8%. This includes the previously mentioned negative full-year impact of around 1% from the Ukraine war, mainly impacting Household Care.

Novozymes is experiencing good momentum across a large part of its portfolio with the focus on innovations and market penetration combined with supportive market conditions. Sales in DKK are expected to be around 8% higher than the organic sales growth outlook.

As events after the interim period - Novozymes signed an agreement to invest intellectual property in 21st.BIO, expected to be completed in the third quarter of 2022. As an effect of the accounting gain the company now expects a solid EBIT-margin of 26-27%, raised from 25-26%. ROIC including goodwill is now expected at 17-18% instead of 16%-17%. The accounting gain is of a non-cash character. Additionally, following the announced sale of Albumedix, Novozymes will as part of the agreement divest its 8% ownership in Albumedix, a company built with Novozymes’ technology platform. The acquisition is subject to customary closing conditions and is expected to close during the second half of the year. Upon closing, the sale will lead to a tax-exempt financial gain and cash flow of around DKK 250 million.

Get in touch

Media relations

Lina Danstrup

Lina Danstrup

Head of External 30 77 05 52

Related articles

Novonesis HQ in Lyngby, Denmark
01.02.24 | 8 minute read

Legacy Novozymes delivers solid last full-year results

Legacy Novozymes is delivering solid growth and earnings in a year characterized by changing market demands, with 6% organic sales growth in Q4 and 5% organic sales growth in 2023. This marks the last financial reporting from legacy Novozymes, and the new company, Novonesis, is already a reality.
Novonesis office
29.01.24 | 6 minute read

The combination of Novozymes and Chr. Hansen is now successfully completed, creating Novonesis – a leading global biosolutions partner

Today, the proposed combination of the legacy companies Novozymes and Chr. Hansen is successfully completed, establishing the company Novonesis. Novonesis is a world-leading biosolutions partner for better business, healthier lives, and a healthier planet. The combined company brings together 10,000 people worldwide and an expertise that spans more than 30 different industries. Novonesis is already assisting companies around the world in meeting both business needs and the needs of the planet.
13.12.23 | 8 minute read

Novozymes and Chr. Hansen announce name of future combined company; Novonesis

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL. Novozymes and Chr. Hansen have announced that the name of the future combined company will be ‘Novonesis’. Novonesis means ‘A new beginning’ and derives from the Greek word ‘genesis’. The name reflects a new era of biosolutions where innovation in biological sciences and technology will offer solutions to solve some of the biggest challenges facing humanity.